# INAVO123 (NCT06790693)

> A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06790693
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer
- Interventions: Inavolisib; Placebo; CDK4/6i; Letrozole
- Enrollment: 450
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- Podcasts: 7
- YouTube: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=inavo123-nct06790693

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06790693", "email": "<work email>"}; the inbox owner confirms by the emailed link.